DelSite, Inc. is in the process of liquidation. The company operates as a research-based, biopharmaceutical and consumer products company with a core technology based on naturally-occurring complex carbohydrates. It also manufactures products for other companies. DelSite is developing its proprietary GelSite technology designed to provide controlled release of peptide and protein-based drugs. The company, through its wholly-owned subsidiary, DelSite Biotechnologies, Inc., focuses on the delivery and stabilization of proteins and peptides for therapeutics and vaccines. The GelVac powder platform is for nasal delivery of vaccines and therapeutics. GelSure is developed for liquid delivery and GPDA is for adjuvant use. Its core platform technology is based on a natural polysaccharide, GelSite polymer. DelSite was formerly known as Carrington Laboratories, Inc. and changed its name to DelSite, Inc. in June 2008. The company was founded in 1973 and is headquartered in Irving, Texas. On April 2, 2009, DelSite, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for DSIIQ